Quoin Pharmaceuticals, Ltd.
QNRX
$7.20
-$0.0796-1.09%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 12.45% | 0.64% | -3.64% | -0.64% | -5.22% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.49% | 60.97% | 8.45% | 18.95% | -5.44% |
| Operating Income | -77.49% | -60.97% | -8.45% | -18.95% | 5.44% |
| Income Before Tax | -87.23% | -63.80% | -12.75% | -21.97% | 6.31% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -87.23% | -63.80% | -12.75% | -21.97% | 6.31% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -87.23% | -63.80% | -12.75% | -21.97% | 6.31% |
| EBIT | -77.49% | -60.97% | -8.45% | -18.95% | 5.44% |
| EBITDA | -78.41% | -61.60% | -8.58% | -19.24% | 5.46% |
| EPS Basic | 54.07% | 83.21% | 82.98% | 76.16% | 81.68% |
| Normalized Basic EPS | 54.07% | 83.21% | 82.98% | 76.16% | 81.68% |
| EPS Diluted | 53.95% | 83.21% | 82.92% | 75.92% | 81.68% |
| Normalized Diluted EPS | 54.07% | 83.21% | 82.98% | 76.16% | 81.68% |
| Average Basic Shares Outstanding | 307.62% | 875.54% | 562.77% | 411.70% | 411.70% |
| Average Diluted Shares Outstanding | 309.76% | 882.35% | 562.50% | 412.50% | 412.50% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |